OAC
NKTR icon

OMERS Administration Corp’s Nektar Therapeutics NKTR Stock Holding History

OMERS Administration Corp’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7,200
Closed -$304K – 1150
2025
Q4 		$304K Buy
+7,200
New +$403K ﹤0.01% 814
2018
Q2 		– Sell
-767
Closed -$1.22M – 455
2018
Q1 		$1.22M Buy
+767
New +$988K 0.01% 278

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OMERS Administration Corp's NKTR Position: Q1 2026 in Review

OMERS Administration Corp sold out of Nektar Therapeutics (NKTR) in Q1 2026, closing a stake of 7,200 shares — an estimated $304K sold.

OMERS Administration Corp first reported a position in NKTR in Q1 2018 and held it in 2 quarters. The position peaked at $1.22M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • OMERS Administration Corp reported no remaining Nektar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 7,200 Nektar Therapeutics shares in Q1 2026, an estimated $304K.
  • OMERS Administration Corp first reported a position in Nektar Therapeutics in Q1 2018 and held it in 2 quarters.
  • OMERS Administration Corp's Nektar Therapeutics position peaked at $1.22M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on OMERS Administration Corp's 13F filing for Q1 2026, filed 15 May 2026.